CagriSema: The Amylin + GLP-1 Combination Reshaping Obesity Research

Two Pathways, One Injection: The Science Behind CagriSema

To understand why researchers are paying attention to this combination, it helps to understand what each component does.

Semaglutide is a GLP-1 (glucagon-like peptide-1) receptor agonist. It slows gastric emptying, reduces appetite signaling in the hypothalamus, and supports glycemic control by stimulating insulin secretion. It is already the active ingredient in Ozempic and Wegovy.

Cagrilintide is a long-acting analog of amylin, a peptide hormone co-secreted with insulin from pancreatic beta cells. Natural amylin acts on calcitonin and amylin receptors in the brainstem's area postrema and other appetite-related regions, promoting satiety, slowing gastric emptying, and suppressing glucagon. Cagrilintide is lipidated for extended half-life, making once-weekly dosing practical.

The hypothesis: because these two hormones act through distinct but complementary pathways, combining them could produce weight reduction that exceeds either agent alone. The REDEFINE trial program tested that hypothesis at scale.

REDEFINE 1: Phase 3 Results in Adults Without Type 2 Diabetes

REDEFINE 1 was a 68-week, double-blind, placebo- and active-controlled Phase 3 trial enrolling 3,417 adults with obesity or overweight plus at least one weight-related comorbidity. Participants did not have type 2 diabetes.

Key findings at week 68:

Roughly 60% of participants on CagriSema lost at least 20% of body weight, and about 23% lost 30% or more. Among participants who had prediabetes at baseline, 88% returned to normoglycemia on the combination.

Results were published in the New England Journal of Medicine in June 2025 and presented at the American Diabetes Association's 85th Scientific Sessions. This is Phase 3 RCT-level evidence, the highest tier before regulatory review, but it is important to note the trial was industry-sponsored and the compound has not yet cleared FDA review.

REDEFINE 2: Phase 3 Results in Adults With Type 2 Diabetes

REDEFINE 2 enrolled 1,206 adults with type 2 diabetes (HbA1c between 7% and 10%) and BMI at or above 27 kg/m squared, randomized 3:1 to CagriSema or placebo for 68 weeks.

At week 68:

The glycemic signal here is notable: the combination appears to address both weight and blood sugar markers simultaneously. Whether this eventually translates into regulatory approvals for the diabetes indication, and what that means for long-term cardiovascular outcomes, requires further study.

How CagriSema Compares to Other Agents in the Obesity Pipeline

The landscape of weight-focused pharmacology has moved quickly. Here is a reference comparison based on Phase 3 data available as of mid-2026:

|---|---|---|---|

A few important caveats on this table. These numbers come from different trial populations, designs, and comparator arms; they are not head-to-head equivalents. A direct head-to-head comparison of CagriSema against tirzepatide (Zepbound) reported that tirzepatide outperformed CagriSema on weight loss in that specific study. Context matters when reading these numbers.

Retatrutide's triple mechanism, adding glucagon receptor agonism to GLP-1 and GIP, appears to drive the highest weight-loss numbers seen to date in clinical research, though longer-term and cardiovascular outcome data are still accumulating.

The unique value proposition of CagriSema is the amylin pathway itself. Amylin and GLP-1 are complementary physiologically, which is why researchers theorize the combination can push past a ceiling that GLP-1 alone hits. Whether that advantage is enough from a market and clinical perspective is something the regulatory and post-approval period will clarify.

What the REDEFINE Trials Showed Beyond Body Weight

Weight loss percentage is the headline, but metabolic researchers track a broader picture. REDEFINE 1 also reported:

These downstream metabolic signals are what make obesity pharmacology research interesting to follow beyond the weight number alone. A compound that changes the scale reading while also shifting [triglycerides](/biomarkers/triglycerides), [hs-CRP](/biomarkers/hs-crp), and blood pressure tells a different story from one that only moves body weight.

Safety Profile: What the Trials Reported

The most common adverse events in REDEFINE 1 and 2 were gastrointestinal: nausea, constipation, vomiting, and diarrhea. In REDEFINE 1, GI events occurred in approximately 79.6% of CagriSema participants versus 39.9% on placebo. Nausea was reported in about 55% of the CagriSema group versus 12.6% on placebo.

The clinical team categorized most GI events as mild to moderate and transient, with symptoms generally most prominent during the dose-escalation phase and decreasing over time. The overall safety profile was described as comparable to the broader GLP-1 receptor agonist class.

This is not a safety endorsement. These are trial population findings under controlled conditions with specific inclusion and exclusion criteria. Individual tolerance varies, and anyone considering any GLP-1 or amylin-class compound must work directly with a licensed healthcare provider.

What to Track: Biomarkers Worth Monitoring

The compound is one variable. What it does to your body over time is a separate, measurable story. Researchers studying GLP-1 and amylin-class protocols commonly monitor a panel of metabolic biomarkers before, during, and after. If you are working with a provider on a protocol in this class, here is a tracking framework worth discussing:

Glycemic markers:

Cardiovascular metabolic markers:

Other relevant signals:

Tracking these over time, not just once, is how you see what is actually changing in your metabolic picture. A 22% weight loss number in a clinical trial is a population average. Your individual biomarker trajectory is what matters for understanding your own response.

[Track this protocol and your labs in one place with MyProtocolStack.](/auth/login?mode=signup)

Regulatory Status and What Comes Next

Novo Nordisk filed the NDA with the FDA in December 2025, citing REDEFINE 1 and 2 as the pivotal evidence. Based on standard FDA review timelines, a decision is expected around late 2026. CagriSema is not approved in the United States, European Union, or any other market as of mid-2026.

If approved, it would enter a market already occupied by tirzepatide and semaglutide-based products, competing on both efficacy data and the novelty of the dual-pathway mechanism. The pipeline question researchers are watching: could amylin analogs like cagrilintide eventually be paired with even broader agents like [retatrutide](/peptides/retatrutide) to extend the efficacy ceiling further? That research is still early-stage.

For now, CagriSema sits in the NDA review phase. Nothing is approved. No off-label or research-context use of any of these compounds should happen outside a supervised clinical relationship.

Frequently Asked Questions

What is CagriSema?

CagriSema is an investigational once-weekly injectable combination of cagrilintide (an amylin analog) and semaglutide (a GLP-1 receptor agonist) developed by Novo Nordisk. It targets two distinct appetite-regulating hormone pathways simultaneously. As of mid-2026, it is not FDA-approved or approved in any other market.

How much weight loss did the REDEFINE trials show?

In REDEFINE 1 (adults without type 2 diabetes, 68 weeks), the CagriSema group lost a mean of approximately 22.7% of body weight versus 3.0% on placebo. In REDEFINE 2 (adults with type 2 diabetes), mean weight loss was approximately 13.7% versus 3.4% on placebo. These are Phase 3 RCT findings from industry-sponsored trials. Individual results in a trial population are not predictive of individual outcomes.

Is CagriSema FDA-approved?

No. An NDA was submitted to the FDA in December 2025. A regulatory decision is expected around late 2026 under standard review. CagriSema is not available for prescription or clinical use outside of authorized research settings. Always consult a licensed healthcare provider.

How does CagriSema compare to tirzepatide or retatrutide?

Tirzepatide targets GLP-1 and GIP receptors. Retatrutide targets GLP-1, GIP, and glucagon. CagriSema pairs GLP-1 with the amylin pathway instead. In a direct head-to-head comparison, tirzepatide outperformed CagriSema on weight loss. The mechanisms are distinct enough that researchers are studying them as potentially complementary rather than interchangeable.

What biomarkers are relevant when tracking a GLP-1 or amylin-class protocol?

Researchers commonly track [HbA1c](/biomarkers/hba1c), [fasting insulin](/biomarkers/fasting-insulin), [ApoB](/biomarkers/apob), [triglycerides](/biomarkers/triglycerides), [hs-CRP](/biomarkers/hs-crp), and cardiovascular vitals like blood pressure. Body composition metrics like waist circumference and weight trend provide the structural picture. Explore the full [biomarker library](/biomarkers) or the [peptide profiles hub](/peptides) for more context on what to monitor.

Sources

1. Novo Nordisk. "CagriSema 2.4 mg / 2.4 mg demonstrated 22.7% mean weight reduction in adults with overweight or obesity in REDEFINE 1, published in NEJM." PR Newswire, June 2025.

2. Novo Nordisk. "Novo Nordisk Files for FDA Approval of CagriSema." Press release, December 2025.

3. Drugs.com. "CagriSema FDA Approval Status." Updated 2026. https://www.drugs.com/history/cagrisema.html

4. American College of Cardiology. "REDEFINE 1 and REDEFINE 2: Greater Weight Loss With Combined Cagrilintide-Semaglutide vs. Either Drug Alone or Placebo." Journal Scan, July 2025.

5. HCPLive. "ADA 2025: CagriSema Demonstrates Dual Benefit in Obesity and Type 2 Diabetes." June 2025.

6. American Heart Association / Hypertension. "CagriSema Reduces Blood Pressure in Adults With Overweight or Obesity: REDEFINE 1." 2025.

7. Novo Nordisk. "CagriSema demonstrated superior HbA1c reduction of 1.91 points and weight loss of 14.2% in adults with type 2 diabetes in the REIMAGINE 2 trial." GlobeNewswire, February 2026.

8. Cardiology in Review. "Cagrilintide: A Long-Acting Amylin Analog for the Treatment of Obesity." 2024. PubMed ID 36883831.

9. NCBI. "What is the pipeline for future medications for obesity?" PMC11971045.

10. Clinical Trials Arena. "Novo Nordisk's CagriSema bested by Lilly's Zepbound in head-to-head trial." 2025-2026.

*MyProtocolStack is a tracking and education tool, not medical advice, diagnosis, or treatment. Always consult a qualified healthcare professional before starting, stopping, or changing any health protocol. CagriSema is an investigational compound; it is not approved by the FDA or any regulatory agency as of mid-2026.*